Capacity to provide informed consent before any trial-related activities
Established T2DM (=3months)
HbA1c = 9% if on triple therapy or = 10% on diet & exercise or monotherapy or dual therapy
Current glucose lowering therapy either mono, dual or triple of any combination of metformin, sulphonylurea, DPP-IV inhibitor, GLP-1 therapy or an SGLT2 +/- diet and exercise
Poorly managed diet controlled diabetes (with HbA1c > 6.5% , not currently taking any glucose lowering therapy, meeting BMI inclusion range)
Body mass index > 30Kg/m2 or > 27.5 Kg/m2 (South Asian),
Diagnosis of T2DM before the age of 60 years of age
Age =18 and = 65 years

NCT02590822_inc_T2
Condition
T2DM
NCT02590822_inc_T3
Temporal
=3months
NCT02590822_inc_T4
Measurement
HbA1c
NCT02590822_inc_T5
Measurement
Capacity to provide informed consent before any trial-related activities
Established T2DM (=3months)
HbA1c = 9
NCT02590822_inc_T6
Value
= 9%
NCT02590822_inc_T7
Value
= 10%
NCT02590822_inc_T8
Scope
= 9% if on triple therapy or = 10%
NCT02590822_inc_T9
Procedure
glucose lowering therapy
NCT02590822_inc_T10
Drug
metformin
NCT02590822_inc_T11
Drug
sulphonylurea
NCT02590822_inc_T12
Drug
DPP-IV inhibitor,
NCT02590822_inc_T13
Drug
GLP-1 therapy
NCT02590822_inc_T14
Drug
SGLT2
NCT02590822_inc_T15
Observation
diet
NCT02590822_inc_T16
Observation
exercise
NCT02590822_inc_T17
Scope
metformin, sulphonylurea, DPP-IV inhibitor, GLP-1 therapy or an SGLT2 +/- diet and exercise
NCT02590822_inc_T18
Condition
diabetes
NCT02590822_inc_T19
Measurement
HbA1c
NCT02590822_inc_T20
Value
> 6.5%
NCT02590822_inc_T21
Negation
not
NCT02590822_inc_T22
Procedure
glucose lowering therapy
NCT02590822_inc_T23
Measurement
Body mass index
NCT02590822_inc_T24
Value
> 30Kg/m2
NCT02590822_inc_T25
Value
> 27.5 Kg/m2
NCT02590822_inc_T26
Scope
> 30Kg/m2 or > 27.5 Kg/m2
NCT02590822_inc_T27
Condition
T2DM
NCT02590822_inc_T28
Person
age
NCT02590822_inc_T29
Value
 the  rs of age
Age =
NCT02590822_inc_T30
Person
Age
NCT02590822_inc_T31
Value
=18 and = 65 years